Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sitesKomoriya, S., Haginoya, N., Kobayashi, S., Nagata, T., Mochizuki, A., Suzuki, M., Yoshino, T., Horino, H., Nagahara, T., Suzuki, M., Isobe, Y., Furugoori, T.
(2005) Bioorg Med Chem 13: 3927-3954
- PubMed: 15911309
- DOI: 10.1016/j.bmc.2005.04.006
- Primary Citation of Related Structures:
- PubMed Abstract:
- Structural basis for chemical inhibition of human blood coagulation factor Xa
Kamata, K., Kawamoto, H., Honma, T., Iwama, T., Kim, S.H.
(1998) Proc Natl Acad Sci U S A 95: 6630
- X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition
Brandstetter, H., Kuhne, A., Bode, W., Huber, R., von der Saal, W., Wirthensohn, K., Engh, R.A.
(1996) J Biol Chem 271: 29988
- Structure of human des(1-45) factor Xa at 2.2 A resolution
Padmanabhan, K., Padmanabhan, K.P., Tulinsky, A., Park, C.H., Bode, W., Huber, R., Blankenship, D.T., Cardin, A.D., Kisiel, W.
(1993) J Mol Biol 232: 947
- Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element
Haginoya, N., Kobayashi, S., Komoriya, S., Yoshino, T., Suzuki, M., Shimada, T., Watanabe, K., Hirokawa, Y., Furugori, T., Nagahara, T.
(2004) J Med Chem 47: 5167
Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with exc ...
Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1mg/kg of compound 75b.
Tokyo R&D Center, Daiichi Pharmaceutical Co. Ltd, 16-13 Kita-Kasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. firstname.lastname@example.org